185 related articles for article (PubMed ID: 22592318)
21. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes.
Li G; Domenico J; Lucas JJ; Gelfand EW
J Immunol; 2004 Aug; 173(4):2383-91. PubMed ID: 15294951
[TBL] [Abstract][Full Text] [Related]
22. Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation.
Figliola R; Busanello A; Vaccarello G; Maione R
J Mol Biol; 2008 Jul; 380(2):265-77. PubMed ID: 18513743
[TBL] [Abstract][Full Text] [Related]
23. The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Coley HM; Safuwan NA; Chivers P; Papacharalbous E; Giannopoulos T; Butler-Manuel S; Madhuri K; Lovell DP; Crook T
Br J Cancer; 2012 Jan; 106(3):482-9. PubMed ID: 22233925
[TBL] [Abstract][Full Text] [Related]
24. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
Joaquin M; Watson RJ
J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
[TBL] [Abstract][Full Text] [Related]
25. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus.
Yokoo T; Toyoshima H; Miura M; Wang Y; Iida KT; Suzuki H; Sone H; Shimano H; Gotoda T; Nishimori S; Tanaka K; Yamada N
J Biol Chem; 2003 Dec; 278(52):52919-23. PubMed ID: 14530263
[TBL] [Abstract][Full Text] [Related]
26. p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.
Takahashi K; Kobayashi T; Kanayama N
Mol Hum Reprod; 2000 Nov; 6(11):1019-25. PubMed ID: 11044465
[TBL] [Abstract][Full Text] [Related]
27. Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.
Foerster F; Braig S; Moser C; Kubisch R; Busse J; Wagner E; Schmoeckel E; Mayr D; Schmitt S; Huettel S; Zischka H; Mueller R; Vollmar AM
Cell Death Dis; 2014 Aug; 5(8):e1398. PubMed ID: 25165884
[TBL] [Abstract][Full Text] [Related]
28. Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth.
Akaishi K; Nakayama J; Sakai K; Kobayashi T; Rutka JT
J Clin Neurosci; 2009 Dec; 16(12):1615-8. PubMed ID: 19822429
[TBL] [Abstract][Full Text] [Related]
29. TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57
Li X; Ruan X; Zhang P; Yu Y; Gao M; Yuan S; Zhao Z; Yang J; Zhao L
Oncogene; 2018 May; 37(21):2773-2792. PubMed ID: 29511350
[TBL] [Abstract][Full Text] [Related]
30. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation.
Kim M; Nakamoto T; Nishimori S; Tanaka K; Chiba T
EMBO Rep; 2008 Sep; 9(9):878-84. PubMed ID: 18660753
[TBL] [Abstract][Full Text] [Related]
31. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101.
Sinuani I; Weissgarten J; Beberashvili I; Rapoport MJ; Sandbank J; Feldman L; Albeck M; Averbukh Z; Sredni B
Nephrol Dial Transplant; 2009 Aug; 24(8):2328-38. PubMed ID: 19321762
[TBL] [Abstract][Full Text] [Related]
32. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.
Ma Y; Cress WD
Oncogene; 2007 May; 26(24):3532-40. PubMed ID: 17173074
[TBL] [Abstract][Full Text] [Related]
34. The long non-coding RNA Kcnq1ot1 controls maternal p57 expression in muscle cells by promoting H3K27me3 accumulation to an intragenic MyoD-binding region.
Andresini O; Rossi MN; Matteini F; Petrai S; Santini T; Maione R
Epigenetics Chromatin; 2019 Jan; 12(1):8. PubMed ID: 30651140
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells.
Nakano N; Urasawa K; Takagi Y; Saito T; Kaneta S; Ishikawa S; Higashi H; Tsutsui H; Hatakeyama M; Kitabatake A
Biochem Biophys Res Commun; 2005 Dec; 338(3):1661-7. PubMed ID: 16259944
[TBL] [Abstract][Full Text] [Related]
36. A Beckwith-Wiedemann-Associated
Stampone E; Bencivenga D; Barone C; Di Finizio M; Della Ragione F; Borriello A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299047
[TBL] [Abstract][Full Text] [Related]
37. Cyclic changes in the expression of p57(kip2) in human endometrium and its regulation by steroid hormones in endometrial stromal cells in vitro.
Kim ST; Lee SK; Gye MC
Reprod Sci; 2012 Jan; 19(1):92-101. PubMed ID: 22064387
[TBL] [Abstract][Full Text] [Related]
38. p57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts.
Reynaud EG; Pelpel K; Guillier M; Leibovitch MP; Leibovitch SA
Mol Cell Biol; 1999 Nov; 19(11):7621-9. PubMed ID: 10523650
[TBL] [Abstract][Full Text] [Related]
39. p57(KIP2) regulates radial glia and intermediate precursor cell cycle dynamics and lower layer neurogenesis in developing cerebral cortex.
Mairet-Coello G; Tury A; Van Buskirk E; Robinson K; Genestine M; DiCicco-Bloom E
Development; 2012 Feb; 139(3):475-87. PubMed ID: 22223678
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of p57Kip2 induces prostate cancer in the mouse.
Jin RJ; Lho Y; Wang Y; Ao M; Revelo MP; Hayward SW; Wills ML; Logan SK; Zhang P; Matusik RJ
Cancer Res; 2008 May; 68(10):3601-8. PubMed ID: 18483241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
